VarSome Premium now with OncoKB™ Integration

We are pleased to announce that OncoKB™, the precision oncology knowledgebase developed by Memorial Sloan Kettering Cancer Center, is now integrated directly into VarSome Premium (version 13.9.0).

OncoKB™ provides curated, evidence-based information on the oncogenic effect and clinical actionability of cancer variants. By incorporating OncoKB™ into VarSome Premium, we give users a faster, more confident route to understanding the therapeutic, diagnostic, and prognostic relevance of somatic variants within our renowned, intuitive interface.

This integration enhances the interpretation of somatic variants by:

• Flagging clinically actionable variants with therapy implications, biomarker associations, or diagnostic relevance, mapped to cancer types.
• Providing structured evidence levels in line with FDA and AMP/ASCO/CAP guidelines, helping laboratories align with regulatory standards.
• Supporting treatment decisions with links to FDA-approved drugs, guidelines, and relevant clinical trials. 

Combined with VarSome’s existing annotation layers, OncoKB™ data helps prioritize variants with the greatest clinical significance. Users can instantly see whether a variant is associated with a targeted therapy or relevant resistance mechanism, reducing the time spent cross-referencing databases and increasing confidence in reporting. 

OncoKB™ data is now also available via the VarSome API, enabling seamless integration into automated somatic workflows.

The addition of OncoKB™ aligns with our continuing goal at Saphetor: to support precision oncology workflows that are faster, clearer, and more clinically useful. If you have any questions, please feel free to contact us at sales@varsome.com or by clicking here. Otherwise, take a look at the clip below to see OncoKB™ in action!